Q2 2019 13F Holders as of 6/30/2019
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
28M
-
Number of holders
-
65
-
Total 13F shares, excl. options
-
34.8M
-
Shares change
-
+11M
-
Total reported value, excl. options
-
$321M
-
Value change
-
+$102M
-
Number of buys
-
47
-
Number of sells
-
-20
-
Price
-
$9.26
Significant Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) as of Q2 2019
75 filings reported holding SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value as of Q2 2019.
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) has 65 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.8M shares
.
Largest 10 shareholders include FMR LLC (6.13M shares), ARK Investment Management LLC (3.79M shares), Redmile Group, LLC (3.62M shares), Flagship Pioneering Inc. (3.2M shares), Nikko Asset Management Americas, Inc. (2.99M shares), BlackRock Inc. (2.67M shares), VANGUARD GROUP INC (1.77M shares), Samsara BioCapital, LLC (1.73M shares), Sumitomo Mitsui Trust Holdings, Inc. (1.59M shares), and DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (1.27M shares).
This table shows the top 65 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.